Physician profile
Scott T Pierce
NPI 1376511444
$2,402.14
in general payments reported to CMS, 2019-2025
32 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $341 · 2021: $295 · 2022: $123 · 2023: $56.93 · 2024: $483 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.12 |
| Education | $230.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $476.03 | 2019-2024 | Darzalex |
| Pfizer INC. | $328.39 | 2019-2025 | |
| Seagen INC. | $199.90 | 2019-2021 | |
| Genentech USA, INC. | $181.28 | 2019-2023 | Tecentriq |
| Novartis Pharmaceuticals Corporation | $181.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $129.88 | 2019-2025 | Opdivo |
| Amgen INC. | $121.65 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $87.49 | 2020-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $84.77 | 2019-2025 | Welireg, Keytruda, Keytruda Qlex |
| Adc Therapeutics America, INC. | $62.93 | 2025 | |
| Genzyme Corporation | $51.17 | 2021 | |
| Gilead Sciences, INC. | $50.56 | 2019-2021 | |
| Lilly USA, LLC | $44.01 | 2020-2024 | Jaypirca, Verzenio, Retevmo |
| Teva Pharmaceuticals USA, INC. | $42.94 | 2019-2020 | |
| Kite Pharma, INC. | $27.09 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.37 | 2024 | Padcev |
| Celgene Corporation | $24.27 | 2025 | Reblozyl |
| Kyowa Kirin, INC. | $23.50 | 2022 | |
| Daiichi Sankyo INC. | $22.78 | 2024 | Injectafer |
| Beigene USA, INC. | $22.41 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $21.98 | 2023 | Libtayo |
| Glaxosmithkline, LLC. | $21.77 | 2025 | Ojjaara |
| Agios Pharmaceuticals, INC. | $20.49 | 2024 | |
| Genmab U.S., INC. | $19.93 | 2025 | Epkinly |
| Servier Pharmaceuticals LLC | $19.69 | 2024 | |
| Iovance Biotherapeutics, INC. | $18.14 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $17.66 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.63 | 2024 | Onivyde |
| Aveo Pharmaceuticals, INC. | $17.33 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $12.47 | 2019 | |
| Eisai INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.